Study wrapper · #1108
GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults.
Hsu AH, Ramirez PT, Chang YH, et al. Annals of oncology. 2026.
DOI: 10.1016/j.annonc.2026.04.013PubMed: 42252247
Editor's note
A target-trial-emulation cohort associating GLP-1 receptor agonist use with lower short-term obesity-associated cancer incidence in nondiabetic adults, with semaglutide and tirzepatide analyzed as a subgroup. As an observational analysis it establishes association only, and the authors call for prospective trials to address causality.
Plain-language abstract
This large database study of obese, nondiabetic US adults found that GLP-1 receptor agonist use, including semaglutide and tirzepatide, was associated with a lower short-term incidence of obesity-associated cancers. The authors note prospective trials are needed to confirm whether the drugs are responsible.
Related coverage
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026